NASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis $36.80 -0.29 (-0.78%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$36.80 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRNX alerts:Sign Up Key Stats Today's Range$36.64▼$37.8050-Day Range$33.67▼$43.5852-Week Range$25.83▼$57.99Volume702,432 shsAverage Volume1.42 million shsMarket Capitalization$3.88 billionP/E RatioN/ADividend YieldN/APrice Target$76.13Consensus RatingModerate Buy Company Overview Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence. The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea. In parallel, Crinetics is advancing CRN04894, a vasopressin V2 receptor antagonist for the management of hyponatremia, and CRN04912, an oral ghrelin receptor inverse agonist being developed for congenital hyperinsulinism. These programs reflect Crinetics’ strategy to build a focused pipeline addressing multiple rare endocrine disorders with high unmet medical need. Founded in 2013 and headquartered in San Diego, California, Crinetics Pharmaceuticals operates with an organizational structure designed to support both in-house discovery and external collaborations. The company engages with academic research centers and clinical investigators across North America and Europe to advance its clinical studies and to explore additional indications for its pipeline candidates. Crinetics’ integrated approach combines medicinal chemistry, translational biology and clinical development expertise under one roof, with the goal of accelerating the path from laboratory to patient care. As a publicly traded company on the NASDAQ under the ticker CRNX, Crinetics maintains a governance framework led by a board of directors and an executive leadership team with deep experience in endocrinology, drug development and regulatory affairs. The company continues to invest in expanding its pipeline and strengthening its scientific capabilities to bring new treatment options to patients with rare hormonal disorders.AI Generated. May Contain Errors. Read More Crinetics Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCRNX MarketRank™: Crinetics Pharmaceuticals scored higher than 44% of companies evaluated by MarketBeat, and ranked 504th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCrinetics Pharmaceuticals has a consensus price target of $76.13, representing about 106.9% upside from its current price of $36.80.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Crinetics Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($4.82) to ($4.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -7.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -7.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crinetics Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.97% of the float of Crinetics Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 10.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.20 News SentimentCrinetics Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Crinetics Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,569,475.00 in company stock.Percentage Held by Insiders3.80% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crinetics Pharmaceuticals' insider trading history. Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRNX Stock News HeadlinesCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026May 22 at 4:05 PM | globenewswire.comLifeSci Capital Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)May 22 at 2:54 PM | theglobeandmail.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 23 at 1:00 AM | Brownstone Research (Ad)Biostar Pharmaceuticals (OTCMKTS:BSPM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) Financial ContrastMay 20 at 5:37 AM | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Raised to Sell at Wall Street ZenMay 17, 2026 | americanbankingnews.comCrinetics Pharmaceuticals Inc CRNXMay 15, 2026 | morningstar.comMFinancial Analysis: Cronos Group (NASDAQ:CRON) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX)May 15, 2026 | americanbankingnews.comIndustry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11%May 14, 2026 | finance.yahoo.comSee More Headlines CRNX Stock Analysis - Frequently Asked Questions How have CRNX shares performed this year? Crinetics Pharmaceuticals' stock was trading at $46.55 at the beginning of the year. Since then, CRNX stock has decreased by 20.9% and is now trading at $36.80. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($1.23) EPS for the quarter, missing analysts' consensus estimates of ($1.22) by $0.01. The business's quarterly revenue was up 2873.4% compared to the same quarter last year. Read the conference call transcript. When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $96 million in an initial public offering on Wednesday, July 18th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' top institutional shareholders include Janus Henderson Group PLC (4.29%), Siren L.L.C. (1.81%), Pictet Asset Management Holding SA (1.80%) and ADAR1 Capital Management LLC (1.08%). Insiders that own company stock include Richard Scott Struthers, Stephen F Betz, Marc Wilson, Jeff E Knight, Tobin Schilke, Dana Pizzuti, Alan Seth Krasner, James Hassard, Matthew K Fust, Coelho Rogerio Vivaldi, Stephanie Okey and Isabel Kalofonos. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/07/2026Today5/23/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, CRNX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRNX CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year Founded2008Price Target and Rating Average Price Target for Crinetics Pharmaceuticals$76.13 High Price Target$95.00 Low Price Target$52.00 Potential Upside/Downside+106.9%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($5.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$465.32 million Net Margins-2,747.18% Pretax Margin-2,746.18% Return on Equity-43.96% Return on Assets-39.61% Debt Debt-to-Equity RatioN/A Current Ratio18.60 Quick Ratio18.56 Sales & Book Value Annual Sales$18.07 million Price / Sales214.74 Cash FlowN/A Price / Cash FlowN/A Book Value$12.15 per share Price / Book3.03Miscellaneous Outstanding Shares105,440,000Free Float101,433,000Market Cap$3.88 billion OptionableOptionable Beta0.28 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CRNX) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
